LEO Pharma has entered into a strategic partnership with ICON to scale clinical trial execution in medical dermatology.
To be operated under the acronym of PACE, this collaboration is expected to support LEO Pharma’s aim to build one of the most effective and efficient clinical portfolio execution organisations in the industry.
Additionally, it is expected to improve dermatology patients’ lives by providing access to innovative clinical trials and the launch of new medicines.
The collaboration will use completely outsourced and functional outsourcing models in a tailored and flexible hybrid approach.
LEO Pharma intends to achieve significant and lean scalability in all expertise areas within clinical development, and drive efficiencies in clinical trials.
It also plans to co-invest in decentralised clinical trials and gain access to a significant number of ICON in-house ancillary services.
LEO Pharma Global research and development (R&R) head and executive vice-president Jörg Möller said: “We’ve been exploring several outsourcing models but found a hybrid sourcing model to be the most efficient.
“Partnering with ICON supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business through scalability and flexibility.
“ICON’s wealth of services and leading position in clinical development will support LEO Pharma’s R&D strategy, building on driving innovation through partnerships and supporting staying competitive.”
ICON is creating a team of more than 500 professionals across its business for providing tailored solutions and capabilities including its FIRECREST site management, its Accellacare site-network, decentralised clinical trial capabilities, and labs for creating strategic advantages in how the trials are delivered.
ICON CEO Steve Cutler said: “ICON is delighted to enter this partnership with LEO Pharma that truly takes advantage of our breadth of capability and expertise.
“We take a flexible and integrated approach when working with our partners, utilising fully outsourced, hybrid, and FSP models that complement our partner’s internal capabilities and enable them to achieve their strategic goals.”
Decentralised Clinical Trial coverage in Clinical Trials Arena is supported by Huma.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.